Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2023, specifically dated September 6, 2023. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It details a specific executive compensation event:
- Executive: Mr. L Miels, Chief Commercial Officer.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Cash payment following the vesting of 25% of an award made on February 14, 2018, under the GlaxoSmithKline Deferred Investment Award Programme.
- Volume: 30,524.840 notional Ordinary Shares.
- Price: £13.7360 per share.
- Value: Gross cash payment of £419,289.21 (subject to applicable tax withholding).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents a routine vesting event for an executive award.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies related to the company's business outlook. It is a regulatory disclosure of a specific transaction date (September 4, 2023).
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Programme for Mr. Miels.
- Confirm the share price of £13.7360 used for the calculation against market data for September 4, 2023.
- Note that this transaction resulted in a cash payout rather than the issuance of new shares.